NeuroSense Strengthens Global Patent Strategy with New Australian Patent for PrimeC Treatments

NeuroSense Expands Global IP Protection Strategy

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotechnology firm in the late stages of clinical development, recently announced a significant advancement in its global intellectual property (IP) protection. The company secured an Australian patent (No. 2022370513) that covers its innovative drug composition, PrimeC, specifically combining ciprofloxacin and celecoxib. This strategic move reinforces NeuroSense's commitment to protecting its proprietary technologies while enhancing its market strategy against severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Growing Global IP Strategy

The newly granted Australian patent follows the approval of a U.S. patent (12,097,185), marking a crucial step in expanding NeuroSense's IP portfolio across international markets. The patent protection for PrimeC extends through October 2042, offering a robust framework that secures exclusive rights for NeuroSense and supports the long-term development and potential commercialization of its therapies.

Alon Ben-Noon, Chief Executive Officer of NeuroSense, emphasized the critical importance of this achievement in the company's strategy. He stated, “Securing patent protection in Australia, in addition to the already granted patent in the US, is an important step in executing our global IP protection strategy for PrimeC.” This sentiment reflects the increasing necessity for companies in the biotechnology realm to establish secure foundations for their innovations in crucial markets.

About PrimeC

PrimeC is NeuroSense's lead candidate, designed as a novel, fixed-dose oral therapy that presents a unique formulation—combining ciprofloxacin and celecoxib in a synchronized, extended-release format. This innovative approach ensures that both pharmaceuticals are delivered in a controlled manner, differentiating it from simple co-administration of drugs. PrimeC aims to address various mechanisms implicated in ALS, including neuroinflammation and iron dysregulation, potentially representing a multi-target solution for modifying disease progression.

As NeuroSense approaches Phase 3 development in ALS, bolstered by positive Phase 2b PARADIGM results, the prospect for PrimeC seems promising. The clinical readiness of PrimeC highlights its potential to make meaningful contributions to treating ALS and Alzheimer’s disease, conditions notorious for their devastating effects and currently limited therapeutic options.

The Unmet Need in Neurodegenerative Diseases

The landscape of neurodegenerative diseases presents one of the most substantial unmet medical needs today. ALS, for example, poses a dire prognosis with complete paralysis and a life expectancy of only 2-5 years post-diagnosis for patients. In the U.S. alone, over 5,000 individuals are diagnosed yearly, leading to a disease burden estimated at $1 billion annually.

Similarly, Alzheimer's disease continues to lead the charge as a major cause of dementia, affecting over 30 million people globally. The ongoing search for effective treatments has rendered significant gaps in existing therapies, with most available drugs providing only symptomatic relief without addressing the underlying progression of these diseases.

NeuroSense's commitment to synergistic therapies targeting multiple pathways is a vital aspect in providing hope for patients and families dealing with ALS and Alzheimer's. With their new patent and advances in clinical trials, NeuroSense is strategically positioned to make significant strides in addressing these pressing healthcare challenges.

Conclusion

NeuroSense’s successful patent expansion in Australia represents a pivotal development for the company, facilitating the groundwork needed for the future of PrimeC and supporting their mission to deliver innovative treatments to those affected by neurodegenerative diseases. As the world watches, the progress of NeuroSense could potentially change the landscape of therapeutic options available for ALS, Alzheimer’s, and beyond. Stay tuned for more updates on NeuroSense’s journey as it endeavors to create impactful solutions for some of the most challenging medical conditions today.

For further updates, investors and interested parties can engage with the company via their official website and through social media platforms, including LinkedIn, YouTube, and X.